KINDSTAR GLOBALGENE TECHNOLOGY, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.57 HKD | +1.29% |
|
+0.64% | -6.55% |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
Strengths
- The company appears to be poorly valued given its net asset value.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Sector: Healthcare Facilities & Services
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -6.55% | 189M | - | ||
| -18.58% | 8.15B | B+ | ||
| +47.25% | 3.82B | C+ | ||
| -8.58% | 2.47B | - | ||
| -38.71% | 2.46B | B- | ||
| -10.06% | 2.34B | B- | ||
| -5.44% | 1.88B | C- | ||
| -17.79% | 1.55B | A- | ||
| -40.78% | 1.21B | C+ | ||
| +6.69% | 1.11B | B+ |
Investor Rating
Trading Rating
-
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
-
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
-
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 9960 Stock
- Ratings Kindstar Globalgene Technology, Inc.
